cinacalcet HCl / Generic mfg. - LARVOL DELTA

Switching patients from cinacalcet to etelcalcetide: evaluation of predictors of efficacy in a retrospective cohort study (PubMed, Probl Endokrinol (Mosk)) - "In moderate SHPT (PTH 600-1000 pg/ml) it is possible to achieve the target in most patients, but with higher level, the result worsened. The signs of parathyroid authonomy predicts the insufficient effect better than high baseline PTH level."

Journal • Retrospective data • Renal Disease • Secondary Hyperparathyroidism

Cinacalcet Efficacy in Hyperparathyroidism-Chronic Kidney Disease-Non-Dialysis, Hemodialysis, Peritoneal Dialysis, Kidney Transplantation: Critical Review. (PubMed, Biomedicines) - "In kidney transplant recipients, parathyroidectomy achieved greater normalization of PTH and calcium. Cinacalcet has been shown to reduce mortality in patients on hemodialysis and peritoneal dialysis."

Journal • Review • Cardiovascular • Chronic Kidney Disease • Endocrine Disorders • Musculoskeletal Diseases • Nephrology • Orthopedics • Osteoporosis • Renal Disease • Transplantation

Distinguishing AP2S1 Mediated Familial Hypocalciuric Hypercalcemia from Primary Hyperparathyroidism Helps Clarify Familial Hypercalcemia and Avoid Unnecessary Surgery (ACMG 2026) - "Treatment with cinacalcet, a calcium-sensing receptor activator, can reduce serum calcium and has been tried in patients with symptoms attributed to hypercalcemia...He underwent genetic counseling and then underwent testing with an Hereditary Hyperparathyroidism Panel which included AP2S1, CASR, CDC73, CKDN1B, GNA11, MEN1, RET, and TRPV6. His results showed a heterozygous pathogenic variant in the AP2S1 gene (c.43C>T, p.Arg15Cys) confirming FHH-AP2S1."

Surgery • Constipation • Endocrine Disorders • Gastroenterology • Gastrointestinal Disorder • Metabolic Disorders • Nephrology • Osteoporosis • Renal Calculi • Rheumatology • ARG1 • CASR • CDC73 • GNA11 • TRPV6

Minimal Physiologically-Based Pharmacokinetic Modeling to Predict Concentration-Time Profiles of Poorly Soluble Cinacalcet Hydrochloride in Fasting and Fed State. (PubMed, Eur J Drug Metab Pharmacokinet) - "The mPBPK model can accurately predict the plasma concentration-time curves under both fasted and fed conditions, and provides a new perspective for establishing in vivo-in vitro correlations of drug products such as incomplete in vivo release, sustained/controlled release, and poor absorption."

Journal • PK/PD data

Comparative effectiveness of parathyroidectomy versus cinacalcet in severe secondary hyperparathyroidism among hemodialysis patients in Sudan: a retrospective cohort study. (PubMed, BMC Nephrol) - No abstract available

HEOR • Journal • Retrospective data • Chronic Kidney Disease • Endocrine Disorders • Renal Disease • Secondary Hyperparathyroidism

Cinacalcet therapy in symptomatic 11-year-old girl with familial hypocalciuric hypercalcemia type 3. (PubMed, Pediatr Nephrol) - "After a dose titration and vitamin D3 dose adjustments, a normalization of serum calcium and PTH was achieved, and symptoms improved substantially, although lumbar bone mineral density declined further, and neurological symptoms remained. This case demonstrates cinacalcet as an effective and well-tolerated therapy in FHH3, with unresolved questions regarding skeletal and neurocognitive outcomes."

Journal • Cognitive Disorders • Endocrine Disorders • Genetic Disorders • Metabolic Disorders • Rare Diseases • CASR

SHR6508-301: The Trial of SHR6508 in Secondary Hyperparathyroidism (clinicaltrials.gov) - P3 | N=498 | Completed | Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. | Active, not recruiting ➔ Completed

Trial completion • Endocrine Disorders • Secondary Hyperparathyroidism

Management of Neonatal Severe Hyperparathyroidism due to Homozygous CASR Mutation: Challenges and Literature Insights. (PubMed, Mol Syndromol) - "Despite initial treatment with hydration and furosemide, her hypercalcemia persisted. Cinacalcet was started but failed to control calcium levels, leading to the need for a subtotal parathyroidectomy at 2.5 months of age...Postoperatively, the patient developed hypocalcemia due to hungry bone syndrome and later experienced recurrent hypercalcemia, which was managed with pamidronate followed by calcitriol...Subtotal parathyroidectomy proved essential for controlling hypercalcemia. Continued documentation of NSHPT cases will help improve treatment strategies and outcomes for this rare condition."

Journal • Endocrine Disorders • Metabolic Disorders • CASR

Cinacalcet Perturbs Membrane Permeability of bEND.3 Endothelial Cells and Suppresses Cell Proliferation. (PubMed, Physiol Res) - "These data suggest cinacalcet, in a manner independent of CaSR stimulation and membrane fluidity perturbation, caused membrane leakiness, eventually leading to inhibition of EC proliferation and EC death. Key words Ca2+-sensing receptors " Endothelium " Cinacalcet " Ca2+ " Membrane permeability."

Journal • Oncology

Bone Disease in Primary Hyperparathyroidism. (PubMed, J Musculoskelet Neuronal Interact) - "Non-surgical treatment is recommended in patients who do not meet the criteria for surgical management, in patients who deny surgical treatment or are high-risk surgical patients. The most frequently used agents are bisphosphonates, denosumab, cinacalcet and vitamin D supplementation."

Journal • Review • Endocrine Disorders • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics

Second Chances or Setbacks: The Impact of Parathyroidectomy on Graft Failure Post-Kidney Transplantation. (PubMed, J Am Coll Surg) - "Patients who underwent parathyroidectomy experienced lower rates of kidney transplant failure and dialysis, outperforming Cinacalcet, a finding that should be cautiously interpreted regarding its clinical relevance. Improved electrolyte balance and PTH levels may be associated with a lower rate of renal osteodystrophy."

Journal • Endocrine Disorders • Transplantation

Parathyroidectomy is associated with lower mortality and fewer cardiac complications in patients with secondary hyperparathyroidism. (PubMed, Surgery) - "Parathyroidectomy may provide superior long-term survival and cardiovascular outcomes compared to cinacalcet, even in patients with moderately elevated parathyroid hormone."

Journal • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Endocrine Disorders • Heart Failure • Secondary Hyperparathyroidism • Transplantation

CaR-Derived Column Was Prepared to Discover Multiple Active Constituents Simultaneously From Epimedii Folium. (PubMed, Biomed Chromatogr) - "The results indicated that the immobilized CaR can recognize specifically agonist Ca2+ as well as allosteric modulators cinacalcet and NPS2143, and the four bioactive compounds including epimedin A, epimedin B, epimedin C, and icariin were simultaneously screened from over 100 constituents in one injection of the Epimedii Folium extract...These findings contributed to understanding the action mechanism of the four bioactive compounds with the CaR at the molecular level. Our work broke through the conventional way to isolate the interested molecules first and then testify their pharmacological and pharmacodynamic effects, establishing a rapid approach to discover simultaneously multiple active constituents from an herbal medicine."

Journal

Distinct and Targetable Role of Calcium and Calcium Sensing Receptor in Leukaemia (ASH 2023) - "Treatment of mice with the CaSR agonist cinacalcet and imatinib prolonged survival of mice with CML, while treatment with a CaSR antagonist NPS-2143 significantly reduced tumour burden and prolonged survival of mice with AML in syngeneic and xenogeneic transplantation experiments. In summary, our results suggest that calcium ions, likely originating from the BMM and/or CaSR strongly and differentially influence leukaemia localisation and progression. As an adjunct to existing treatment strategies, targeting of CaSR with specific pharmacologic agonists may be beneficial in CML and B-ALL, while CaSR antagonists may prolong survival of patients with AML."

Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Acute Lymphoblastic Leukemia • Chronic Myeloid Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR • CASR • GLI2

Six-Month Real-World Outcomes of Cinacalcet in Patients on Hemodialysis Who Have Secondary Hyperparathyroidism (SHPT) in Quito, Ecuador (KIDNEY WEEK 2025) - "Conclusion Cinacalcet effectively reduced PTH levels over six months in chronic hemodialysis patients, including those with nodular parathyroid disease. These real-world results support its role in SHPT management in Latin American settings, where clinical data remain scarce."

Clinical • Real-world • Real-world evidence • Endocrine Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Renal Disease • Secondary Hyperparathyroidism

Long-Term Efficacy of Etelcalcetide in a Patient on Hemodialysis with Refractory Secondary Hyperparathyroidism: A 15-Month Follow-Up Case Report (KIDNEY WEEK 2025) - "Persistent SHPT (baseline iPTH 200–500 pg/mL) proved resistant to sequential therapies: paricalcitol (5 μg biweekly, halted for hypercalcemia and hyperphosphatemia) and cinacalcet (25–50 mg daily, discontinued for severe dyspepsia). Dynamic monitoring of calcium and iPTH is crucial for maintaining therapeutic stability. Changes in serum levels of parathyroid hormone (PTH), calcium (Ca), and phosphorus (P)"

Case report • Clinical • Dyspepsia • Endocrine Disorders • Metabolic Disorders • Nephrology • Secondary Hyperparathyroidism • Vasculitis

Simple but Unrecognized: Spurious High PTH Levels from Blood Drawn from Arm with Parathyroid Autograft (KIDNEY WEEK 2025) - "Cinacalcet was discontinued after two days...A case series of 4 patients inappropriately referred for parathyroidectomy to a single ENT practice suggests that it may not be infrequent. It is recommended that PTH levels are obtained from the arm contralateral to the autotransplant site to ensure that the values reflect systemic levels."

Asthma • Cardiovascular • Chronic Kidney Disease • Endocrine Disorders • Immunology • Peripheral Arterial Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases

Parathyroidectomy in ESRD: The Challenge of Determining the Right Patient (KIDNEY WEEK 2025) - "One can argue that we traded the cinacalcet for the dependence on liquid calcium supplementation. One could also consider whether she would have tolerated etelcalcetide but the medication is also associated with gastrointestinal side effects. After her parathyroidectomy, the parathyroid hormone level is lower, but the patient continues to suffer from chronic gastroparesis and now chronic hypocalcemia and hypoparathyroidism. It could be helpful to have a specialist in bone health and ESRD, which may not be available in every facility, in guiding treatment plans."

Clinical • Chronic Kidney Disease • Endocrine Disorders • Gastrointestinal Disorder • Hypoparathyroidism • Nephrology • Renal Disease

Management Patterns of Post-Kidney Transplant Hyperparathyroidism (KIDNEY WEEK 2025) - "Treatment included PTX in 24.2% and cinacalcet in 70.5%...Our findings highlight the need for more consistent guidelines for evaluation and treatment of post-transplant HPT and its complications. We also highlight the need for uniform guidance for utilization of sestamibi scans and DEXA."

Anemia • Chronic Kidney Disease • Endocrine Disorders • Genetic Disorders • Hematological Disorders • Nephrology • Orthopedics • Polycystic Kidney Disease • Transplantation

Increased Mortality Rate with Cinacalcet vs. Parathyroidectomy in Patients with Secondary Hyperparathyroidism: Systematic Review and Meta-Analysis (KIDNEY WEEK 2025) - "No significant differences were observed between the two treatments for other outcomes, including cardiovascular events, fractures, or persistent hypocalcemia. These findings suggest that while cinacalcet may be a viable alternative, PTX remains the preferred treatment due to its association with lower mortality rates in SHPT patients"

Retrospective data • Review • Cardiovascular • Endocrine Disorders • Musculoskeletal Diseases • Nephrology • Renal Disease • Secondary Hyperparathyroidism

Etelcalcetide Use Rates Decrease and Parathyroidectomy Rates Increase Following the Incorporation of Calcimimetics into the ESKD Bundle (KIDNEY WEEK 2025) - "Calcimimetics, such as cinacalcet and etelcalcetide (ETEL), are used to manage SHPT and reduce the risk of PTX. After TDAPA, PTX rates rose from 2.9 to 4.8 and 4.6 to 6.5 per 1,000 pt-years in S/MDOs and Black pts, respectively. Conclusion These findings highlight the impact of reimbursement policy on clinical practice and pt outcomes, underlining the unintended consequences of reducing access to effective therapies, increasing health disparities, and potentially suppressing future therapeutic innovation."

Endocrine Disorders • Nephrology • Secondary Hyperparathyroidism

Efficacy and Safety of MT1013 in Patients with Secondary Hyperparathyroidism Undergoing Maintenance Dialysis (KIDNEY WEEK 2025) - P2 | "Bone Mineral Density (BMD) in femoral neck and lumbar spine was significantly improved (p＜0.05) at Week 53; since the inclusion criteria requires a minimal “wash-out” period of cinacalcet only for 8 days, the further improvement of BMD is likely to come from the novel target “OGP”...Conclusion MT1013 presents great efficacy and safety in patients with SHPT undergoing maintenance dialysis. By imposing an additional OGP target beyond traditional CaSR, MT1013 not only controls iPTH but also promotes bone formation, suggesting its potential innovative therapeutic role in those patients."

Clinical • Chronic Kidney Disease • Endocrine Disorders • Gastrointestinal Disorder • Secondary Hyperparathyroidism

Etelcalcetide for Secondary Hyperparathyroidism in Cinacalcet-Resistant Patients on Hemodialysis: A Real-World Multicenter Study (KIDNEY WEEK 2025) - "Conclusion Our real-world multicenter study showed that Etelcalcetide was effective and well tolerated in HD patients with sHPT who are resistant or intolerant to cinacalcet. It enabled most patients to achieve guideline-recommended targets in a relatively short timeframe."

Clinical • Real-world • Real-world evidence • Chronic Kidney Disease • Endocrine Disorders • Nephrology • Secondary Hyperparathyroidism

PTH-Independent Hypercalcemia After Kidney Transplantation Caused by Redistribution from Soft-Tissue Calcifications (KIDNEY WEEK 2025) - "He underwent subtotal parathyroidectomy (PTX) 4 months post-transplantation due to persistent hypercalcemia despite maximum dose cinacalcet...We propose that PIHC was caused by mobilization of calcium from calcified tissues to the bloodstream. Tx: Transplantation, PTX: Parathyroidectomy"

Endocrine Disorders • Hematological Malignancies • Metabolic Disorders • Multiple Myeloma • Nephrology • Renal Disease • Transplantation

Pseudoclubbing with Tumoral Calcinosis and Acro-Osteolysis (KIDNEY WEEK 2025) - "Despite being on maximum dose of cinacalcet, phosphorous binder, and calcitriol, patient’s parathyroid hormone was greater than 2000...Continuous monitoring of labs, individualized treatment plans, and proactive management of complications are vital for improving quality of life and prognosis in patients with advanced renal disease and associated endocrine disorders. Further research is needed to explore optimal management practices for patients with similar presentations, including rare manifestations like pseudoclubbing."

Antibody-mediated Rejection • Chronic Kidney Disease • Endocrine Disorders • Metabolic Disorders • Nephrology • Oncology • Secondary Hyperparathyroidism • Transplant Rejection